Plain-English translation of NCT07021066 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it can help people with advanced cancers that have already been treated with other drugs but are still growing. The medication works by targeting a specific protein called CLDN18.2 that appears on certain cancer cells. Researchers want to learn whether this treatment is safe, how the body processes it, and whether it can help shrink tumors.
People with advanced gastric, pancreatic, esophageal, and bile duct cancers often run out of standard treatment options, and their cancers continue to grow despite previous therapies. This trial exists to offer a new treatment option for patients in this situation and to determine if targeting CLDN18.2 can be an effective approach.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion on the first day of each 21-day treatment cycle. The trial has three phases: researchers will start by testing lower doses to find the safest dose, then expand to treat more people at that dose. You will need to visit the clinic regularly for blood tests, imaging scans, and check-ups to monitor how you are responding and to watch for any side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States